Novartis Receives FDA Accelerated Approval for Vanrafia® in Treatment of Primary IgA Nephropathy

Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...

April 03, 2025 | Thursday | News
Genentech Reports Phase III MUSETTE Trial Results for Ocrevus® Showing No Additional Benefit from Higher Dose in Relapsing MS

Genentech, a member of the Roche Group, announced  that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...

April 03, 2025 | Thursday | News
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from China’s NMPA for Melanoma Treatment

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...

April 02, 2025 | Wednesday | News
Yingli Pharma Receives FDA Clearance to Launch Phase 3 Trial for Linperlisib in Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...

April 02, 2025 | Wednesday | News
Castle Biosciences to Present Key Data on DecisionDx-Melanoma at EADO 2025 Congress

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the ...

April 02, 2025 | Wednesday | News
Inventiva Completes Patient Enrollment in Phase 3 NATiV3 Trial for MASH Treatment

Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...

April 02, 2025 | Wednesday | News
Franco Cavaleri's Groundbreaking Study Challenges Amyloid β-Peptides' Role in Alzheimer's Disease

Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has publis...

April 01, 2025 | Tuesday | News
Hoth Therapeutics Receives USPTO Filing Receipt for New Patent on HT-001 Formulation

 Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, announced that it has received an official Filing Rec...

April 01, 2025 | Tuesday | News
Merck Exercises Global Commercialization Option for Pimicotinib, Marking a Milestone in Partnership with Abbisko Therapeutics

Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...

April 01, 2025 | Tuesday | News
Alnylam Presents New Data from HELIOS-B Trial at ACC.25, Highlighting Vutrisiran’s Impact on ATTR-CM Treatment

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced moderated poster presentations of new data from the landmark HELIOS-B...

March 31, 2025 | Monday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News
Novartis Announces FDA Approval for Expanded Use of Pluvicto® in mCRPC, Tripling Eligible Patient Access

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...

March 31, 2025 | Monday | News
China Grants Breakthrough Therapy Designation to Innovent’s IBI363 for Hard-to-Treat Melanoma

Innovent Biologics, Inc.  a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...

March 31, 2025 | Monday | News
Thermo Fisher and Chan Zuckerberg Institute Partner to Advance Cryo-EM Technology for Breakthrough Biological Imaging

 Thermo Fisher Scientific Inc., the world leader in serving science, has announced a Technology Alliance Agreement with the Chan Zuckerberg Institute ...

March 28, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close